Jun 30 2004
Skinvisible, Inc announced through it’s wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. that it has received notice from the United States Patent and Trademark Office that its patent application for “Topical Composition, Topical Composition Precursor, and Methods For Manufacturing And Using” has issued as U.S. Patent Number 6,756,059.
The patent is directed at manufacturing topical polymer-based delivery system compositions and includes disclosure of various "Topical Compositions and Methods for Manufacturing and Using the Compositions". A divisional application is pending, directed at "Topical Composition and Methods for Using the Composition". The Company has registered the name “Invisicare®” to identify the fifteen different polymer compositions it has developed to date.
When topically applied, products incorporating "Invisicare®" adhere to the skin's outer layers forming a protective bond that resists both wash-off and perspiration for extended periods of time, while delivering targeted levels of active ingredients to the skin. Utilizing its technologies, the Company has developed and tested antibacterial/antimicrobial hand sanitizers, skincare moisturizers, sunscreens, sunless tanners, acne, psoriasis, eczema, tooth whitener and other topical OTC formulations.
Terry Howlett, the Companies President, states, "This will greatly assist our customer base of both Cosmetic and Pharmaceutical companies in offering protection for their proprietary products".
"Of significant note" says Skinvisible® Chemist and Inventor, Dr. James Roszell, "is that Invisicare® offers distinct advantages for drug delivery over conventional creams and ointments". Invisicare® offers enhanced skin adherence due to sustained drug delivery for longer periods of time.
For more information on drug release systems, click here.